BioHarvest Sciences (NASDAQ:BHST) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

BioHarvest Sciences (NASDAQ:BHST) issued its quarterly earnings results on Tuesday. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01, FiscalAI reports. The firm had revenue of $7.87 million during the quarter, compared to analyst estimates of $9.31 million. BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%.

BioHarvest Sciences Stock Performance

Shares of BHST stock traded down $0.07 on Thursday, hitting $1.68. The stock had a trading volume of 97,403 shares, compared to its average volume of 35,231. The stock’s 50 day moving average is $1.65 and its 200-day moving average is $3.11. The firm has a market capitalization of $32.97 million, a price-to-earnings ratio of -3.23 and a beta of 0.93. BioHarvest Sciences has a 52-week low of $1.37 and a 52-week high of $8.30.

Analyst Ratings Changes

A number of analysts have recently issued reports on BHST shares. Roth Capital decreased their target price on BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Maxim Group reduced their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioHarvest Sciences presently has a consensus rating of “Hold” and a consensus target price of $6.50.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.